Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China
Overview
In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal cord.In 2004, Lennon and other persons found highly specific AQP4(aquaporin 4)antibodies in NMO patients'sera, and further differentiated between NMO and MS, confirming that NMO is an independent disease.At present, NMO has been widely recognized as an idiopathic and severe demyelinating disease of the central nervous system.In 2015, the international NMO diagnostic team developed the diagnostic criteria based on highly specific AQP4 antibodie.Up to now, in China, there is no data on the number of NMOSD patients, the rate of misdiagnosis, the treatment methods, and the prognosis.This study is committed to build China's NMOSD big data platform to provide the basis for diagnosis, treatment and prognosis of the disease.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: April 2020
Interventions
- Diagnostic Test: serum AQP4-antibody testing method
- there are different methods of testing serum AQP4-antibody
Arms, Groups and Cohorts
- positive
- serum AQP4-antibody is positive
- negtive
- serum AQP4-antibody is negtive
Clinical Trial Outcome Measures
Primary Measures
- misdiagnosis rate
- Time Frame: 3 years
- misdiagnosis rate of NMOSD
Participating in This Clinical Trial
Inclusion Criteria
1. more than 14 years old 2. Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015 Exclusion Criteria:
1. less than 14 years old 2. NOT Compliance with the diagnostic standard by the NMO International Diagnostic team in 2015
Gender Eligibility: All
Minimum Age: 14 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Beijing Tongren Hospital
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.